Screening for prostate cancer: Explaining new trial results and their implications to patients

Medical Journal of Australia

Volumn 191, Issue 4, 2009, Pages 226-229

  Barratt, Alexandra L ^a,b   Stockler, Martin R ^a,b,c  

^a Department of Epidemiology ^*  (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c SYDNEY CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; HUMAN; LOWER URINARY TRACT SYMPTOM; MORTALITY; PATIENT CARE; PROSTATE CANCER; PROSTATECTOMY; REVIEW; ARTICLE; AUSTRALIA; BLOOD; DECISION MAKING; EVIDENCE BASED MEDICINE; INTERPERSONAL COMMUNICATION; MALE; MASS SCREENING; OUTCOME ASSESSMENT; PATIENT EDUCATION; PROSTATE TUMOR; RISK ASSESSMENT;

AUSTRALIA; COMMUNICATION; DECISION MAKING; EVIDENCE-BASED MEDICINE; HUMANS; MALE; MASS SCREENING; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT EDUCATION AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 70349579099     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2009.tb02760.x     Document Type: Review

References (18)

1. Tracey EA, Alam N, Chen W, Bishop J. Cancer in New South Wales: incidence and mortality 2006. Sydney: Cancer Institute NSW, 2008. http://www. cancerinstitute.org.au/cancer-inst/publications/pdfs/er-2008-02-cim2008-full. pdf (accessed Jul 2009).
2. Australian Institute of Health and Welfare. Australian cancer incidence and mortality (ACIM) books. Prostate cancer. Canberra: AIHW, 2007. http://www.aihw.gov.au/cancer/data/acim-books/index.cfm (accessed Jul 2009).
3. Andriole GL, Crawford ED, Grubb RL 3rd, et al, for the PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-1319.
4. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328.
5. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-878. (Pubitemid 36833878)
6. Screening for prostate cancer. In: HSTAT: guide to clinical preventive services. 3rd ed: recommendations and systematic evidence reviews, guide to community preventive services. US Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. http://www.ncbi.nlm.nih.gov/ books/bv.fcgi?rid=hstat3.chapter.3159 (accessed Jul 2009).
7. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate cancer survivors. N Engl J Med 2008; 358: 1250-1261. (Pubitemid 351439226)
8. Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002; 347: 790-796. (Pubitemid 34988337)
9. Medd JCC, Stockler MR, Collins R, Lalak A. Measuring men's opinions of prostate needle biopsy. ANZ J Surg 2005; 75: 662-664. (Pubitemid 41648195)
10. Gigerenzer G, Edwards A. Simple tools for understanding risks: from innumeracy to insight. BMJ 2003; 327: 741-744. (Pubitemid 37176763)
11. Barratt A, Trevena L, Davey HM, McCaffery K. Use of decision aids to support informed choices about screening. BMJ 2004; 329: 507-510. (Pubitemid 39158906)
12. US Department of Health and Human Services. Agency for Healthcare Research and Quality. US Preventive Services Task Force. Prostate cancer screening. Recommendation statement. Aug 2008. http://www.ahrq.gov/clinic/ uspstf/uspsprca.htm (accessed Jul 2009).
13. Wakefield CE, Meiser B, Gaff CL. A multidisciplinary overview of the issues faced by unaffected men with a family history of prostate cancer. J Urol 2008; 180: 38-46.
14. Howard K, Barratt A, Mann G, Patel M. A model of the outcomes of PSA screening for low and high risk men: information to support informed choices. Arch Intern Med 2009. In press.
15. Pinnock C, Marshall V. Troublesome lower urinary tract symptoms in the community: a prevalence study. Med J Aust 1997; 167: 72-75. (Pubitemid 27359126)
16. American Urological Association BPH Symptom Index Questionnaire. http://godot.urol.uic.edu/~web/ASIS.html (accessed Jul 2009).
17. de la Rosette J, Alivizatos G, Madersbacher S, et al. Guidelines on benign prostatic hypertrophy. Arnhem, Netherlands: European Association of Urology, 2006. http://www.uroweb.org/fileadmin/user-upload/Guidelines/11%20BPH. pdf (accessed Jul 2009).
18. Kaplan SA. Update on the American Urological Association Guidelines for treatment of benign prostatic hypertrophy. Rev Urol 2006; 8 Suppl 4: S10-S17.